Glenview Trust Co grew its holdings in shares of Medtronic plc. (NYSE:MDT) by 1.3% in the fourth quarter, Holdings Channel reports. The fund owned 59,767 shares of the medical technology company’s stock after purchasing an additional 776 shares during the period. Glenview Trust Co’s holdings in Medtronic were worth $4,826,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of MDT. BDO Wealth Advisors LLC bought a new stake in shares of Medtronic during the 2nd quarter valued at about $103,000. Motco boosted its position in shares of Medtronic by 8.7% during the 2nd quarter. Motco now owns 1,239 shares of the medical technology company’s stock valued at $110,000 after acquiring an additional 99 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Medtronic by 21.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock valued at $114,000 after acquiring an additional 290 shares during the last quarter. Blue Chip Partners Inc. bought a new stake in shares of Medtronic during the 3rd quarter valued at about $118,000. Finally, Westwood Holdings Group Inc. bought a new stake in shares of Medtronic during the 2nd quarter valued at about $151,000. Hedge funds and other institutional investors own 81.97% of the company’s stock.

A number of analysts have recently issued reports on MDT shares. SunTrust Banks reiterated a “buy” rating and set a $96.00 price target on shares of Medtronic in a research report on Friday, November 3rd. Bank of America upgraded Medtronic from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Argus upgraded Medtronic from a “hold” rating to a “buy” rating and lifted their price target for the company from $81.27 to $95.00 in a research report on Tuesday, December 12th. They noted that the move was a valuation call. Oppenheimer reissued a “buy” rating on shares of Medtronic in a report on Thursday, December 21st. Finally, Needham & Company LLC reissued a “buy” rating and set a $94.00 price objective on shares of Medtronic in a report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have issued a buy rating to the stock. Medtronic presently has an average rating of “Buy” and a consensus price target of $90.10.

In other Medtronic news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.02, for a total value of $1,264,320.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Richard Kuntz sold 78,526 shares of Medtronic stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total value of $6,769,726.46. Following the completion of the transaction, the vice president now directly owns 149,761 shares in the company, valued at $12,910,895.81. The disclosure for this sale can be found here. Insiders sold a total of 136,684 shares of company stock worth $11,582,596 over the last ninety days. Insiders own 0.31% of the company’s stock.

Medtronic plc. (NYSE MDT) opened at $79.48 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 2.05. The company has a market capitalization of $107,576.03, a P/E ratio of 17.13, a price-to-earnings-growth ratio of 2.19 and a beta of 0.93. Medtronic plc. has a 12 month low of $75.71 and a 12 month high of $89.72.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.08. The business had revenue of $7.05 billion for the quarter, compared to analysts’ expectations of $7.05 billion. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The business’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.12 EPS. equities analysts predict that Medtronic plc. will post 4.76 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, January 19th. Shareholders of record on Friday, December 29th were paid a $0.46 dividend. The ex-dividend date was Thursday, December 28th. This represents a $1.84 dividend on an annualized basis and a yield of 2.32%. Medtronic’s dividend payout ratio (DPR) is currently 50.41%.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/11/medtronic-plc-mdt-shares-bought-by-glenview-trust-co.html.

Medtronic Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.